Drugs / Recombinant herpes zoster vaccine with high-dose adjuvant
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06932523 | Apr 2025 → Jun 2026 overdue | herpes zoster | Shanghai Institute Of Biological Products | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant herpes zoster vaccine with high-dose adjuvant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06932523 ↗ |
| Known as | RHZV | “The purpose of this clinical study is to evaluate the safety and immunogenicity of receiving two doses of recombinant herpes zoster vaccine (CHO cells) (RHZV) in healthy...” NCT06932523 ↗ |
| Modality | Vaccine | “recombinant herpes zoster vaccine (CHO cells) (RHZV)” NCT06932523 ↗ |
| Route | Intramuscular | “Intramuscular injection” NCT06932523 ↗ |